Fluorodeoxyuridine mediated cell cycle synchronization in S-phase increases the Auger radiation cell killing with125I-iododeoxyuridine

NuklearMedizin

Volumn 48, Issue 6, 2009, Pages 233-242

  Perillo Adamer, F ^a   Kosinski, M ^a   Dupertuis, Y M ^b   Viertl, D ^a   Bischof Delaloye, A ^a   Buchegger, Franz ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

125I iododeoxy uridine; Auger radiation treatment; Cell cycle synchronization; Fluorodeoxyuridine; Glioblastoma

Indexed keywords

FLOXURIDINE; IDOXURIDINE;

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL KILLING; CELL SURVIVAL; CELL SYNCHRONIZATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; RADIATION INJURY;

APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS DIVISION; CELL SURVIVAL; FLOXURIDINE; GLIOBLASTOMA; HUMANS; RADIATION DOSAGE;

EID: 73649130284     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0247     Document Type: Article

References (42)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003; 361: 323-331
2. 124I]iododeoxyuridine. Cancer Res 2000; 60: 624-635.
3. Braithwaite AW, Royds JA, Jackson P. The p53 story: layers of complexity. Carcinogenesis 2005; 26: 1161-1169.
4. Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin Oncol 2003; 30: 4-9.
5. Bresnick E, Thompson UB. Properties of deoxythymidine kinase partially purified from animal tumors. J Biol Chem 1965; 240: 3967-3974.
6. Buchegger F, Perillo-Adamer F, Dupertuis YM, Bischof Delaloye A. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging 2006; 33: 1352-1363.
7. Chi KH, Wang HE, Chen FD et al. Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model. J Nucl Med 2001; 42: 345-351.
8. Commerford SL. Biological stability of 5-iodo-2′-deoxyuridine labelled with iodine-125 after its incorporation into the deoxyribonucleic acid of the mouse. Nature 1965; 206: 949-950.
9. Dupertuis YM, Vazquez M, Mach JP et al. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res 2001; 61: 7971-7977.
10. Eidinoff ML, Cheong L, Rich MA. Incorporation of unnatural pyrimidine bases into deoxyribonucleic acid of mammalian cells. Science 1959; 129: 1550-1551.
11. Foulon CF, Adelstein SJ, Kassis AI. Kit formulation for the preparation of radiolabeled iododeoxyuridine by demetallation. J Nucl Med 1996; 37: 1S-3S.
12. Foulon CF, Zhang YZ, Adelstein SJ, Kassis AI. Instantaneous preparation of radiolabeled 5-iodo-2′-deoxyuridine. Appl Radiat Isot 1995; 46: 1039-1046.
13. Freudenberg R, Andreeff M, Oehme L, Kotzerke J. Dosimetry of cell-monolayers in multiwell plates. Nuklearmedizin 2009; 48: 120-126.
14. Garrett C, Wataya Y, Santi DV. Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo- and 5-iodo-2′-deoxyuridylate. Biochemistry 1979; 18: 2798-2804.
15. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004; 31: 635-644.
16. Howell RW, Narra VR, Sastry KS, Rao DV. On the equivalent dose for Auger electron emitters. Radiat Res 1993; 134: 71-78.
17. Kassis AI. The amazing world of auger electrons. Int J Radiat Biol 2004; 80: 789-803.
18. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005; 46 Suppl 1: 4S-12S.
19. Kassis AI, Dahman BA, Adelstein SJ. In vivo therapy of neoplastic meningitis with methotrexate and 5. Acta Oncol 2000; 39: 731-737.
20. 125I in mammalian cells. Radiat Res 1987; 111: 305-318.
21. 125I]iodo-2′-deoxyuridine in mammalian cells following treatment with 5-fluoro-2′-deoxyuridine. J Nucl Biol Med 1991; 35: 167-173.
22. 125I]iodo-2′-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int J Radiat Biol 2004; 80: 941-946.
23. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987; 109: 78-89.
24. 125I]iodo- 2′-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res 1990; 50: 5199-5203.
25. Klecker RW Jr, Jenkins JF, Kinsella TJ et al. Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodo uracil and endogenous pyrimidine modulation. Clin Pharmacol Ther 1985; 38: 45-51.
26. Mirimanoff RO, Gorlia T, Mason W et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006; 24: 2563-2569.
27. Neshasteh-Riz A, Angerson WJ, Reeves JR et al. Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters. Br J Cancer 1997; 75: 493-499.
28. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol 1996; 41: 1973-1992.
29. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005; 109: 93-108.
30. Parsels LA, Zellars RC, Loney TL et al. Prevention of fluorodeoxyuridine-induced cytotoxicity and DNA damage in HT29 colon carcinoma cells by conditional expression of wild-type p53 phenotype. Mol Pharmacol 1997; 52: 600-605.
31. 125I-iododeoxyuridine. Eur J Nucl Med Mol Imaging 2006; 33: 613-620.
32. 125I-UdR loss technique. Strahlenther Onkol 1987; 163: 723-728.
33. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines. J Nucl Med 2007; 48: 1000-1007.
34. 125I] iodo-2′-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy. Nucl Med Commun 2004; 25: 461-468.
35. Sedelnikova OA, Panyutin IG, Thierry AR, Neumann RD. Radiotoxicity of iodine-125-labeled oligodeoxyribonucleotides in mammalian cells. J Nucl Med 1998; 39: 1412-1418.
36. 3H]thymidine incorporation by Mycoplasma arginini-infected cells due to enzymatic cleavage of the nucleoside. Eur J Immunol 1985; 15: 692-696.
37. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
38. Thames HD, Hendry JH. Fractionation in radiotherapy: Taylor and Francis; 1987: 297.
39. Van Meir EG, Kikuchi T, Tada M et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994; 54: 649-652.
40. Wendisch M, Drechsel J, Freudenberg R et al. Cellular damage in vitro - Influence of β-energy and intra cellular radionuclide uptake. Nuklearmedizin 2009; 48: 208-214.
41. 125I]-iododeoxyuridine in two human glioblastoma cell lines. Nucl Med Commun 2000; 21: 947-953.
42. Xue LY, Butler NJ, Makrigiorgos GM et al. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA 2002; 99: 13765-13770.